<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sibmed</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский научный медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Сибирский научный медицинский журнал</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-2512</issn><issn pub-type="epub">2410-2520</issn><publisher><publisher-name>ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18699/SSMJ20250518</article-id><article-id custom-type="elpub" pub-id-type="custom">sibmed-2450</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOMEDICINE</subject></subj-group></article-categories><title-group><article-title>Монофенольный антиоксидант комбинированного действия ТС-13 ускоряет восстановление волосяного покрова у мышей при моделировании алопеции, индуцированной химиотерапией</article-title><trans-title-group xml:lang="en"><trans-title>The dual-action monophenolic antioxidant TS-13 accelerates hair coat restoration in a mouse model of chemotherapy-induced alopecia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2367-0114</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меньщикова</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Menshchikova</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Меньщикова Елена Брониславовна, д.м.н.</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Elena B. Menshchikova, doctor of medical sciences</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">lemen7383@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5817-6055</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Серых</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Serykh</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Серых Анастасия Евгеньевна</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Anastasia E. Serykh</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">rasiel1996@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-2054-3552</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ромах</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Romakh</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ромах Лидия Петровна</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Lidia P. Romakh</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">ramstein24@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7640-4867</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петрова Екатерина Сергеевна, к.т.н.</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Ekaterina S. Petrova, candidate of technical sciences</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">peteka2020@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3397-8067</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Храпова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khrapova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Храпова Марина Валерьевна, к.б.н.</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Marina V. Khrapova, candidate of biological sciences</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">marina.khrapova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0238-4533</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чечушков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chechushkov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чечушков Антон Владимирович, к.м.н.</p><p>630117, г. Новосибирск, ул. Тимакова, 2</p></bio><bio xml:lang="en"><p>Anton V. Chechushkov, candidate of medical sciences</p><p>630117, Novosibirsk, Timakova st., 2</p></bio><email xlink:type="simple">achechushkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олейник</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Oleynik</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олейник Алёна Сергеевна, к.х.н.</p><p>630126, г. Новосибирск, ул. Вилюйская, 28</p></bio><bio xml:lang="en"><p>Alyona S. Oleynik, candidate of chemical sciences</p><p>630126, Novosibirsk, Vilyuyskaya st., 28</p></bio><email xlink:type="simple">oleinikaliona@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6022-934X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кандалинцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kandalintseva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандалинцева Наталья Валерьевна, д.х.н.</p><p>630126, г. Новосибирск, ул. Вилюйская, 28</p></bio><bio xml:lang="en"><p>Natalya V. Kandalintseva, doctor of chemical sciences</p><p>630126, Novosibirsk, Vilyuyskaya st., 28</p></bio><email xlink:type="simple">aquaphenol@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФИЦ фундаментальной и трансляционной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Center of Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Новосибирский государственный педагогический университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Pedagogical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2025</year></pub-date><volume>45</volume><issue>5</issue><fpage>211</fpage><lpage>219</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Меньщикова Е.Б., Серых А.Е., Ромах Л.П., Петрова Е.С., Храпова М.В., Чечушков А.В., Олейник А.С., Кандалинцева Н.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Меньщикова Е.Б., Серых А.Е., Ромах Л.П., Петрова Е.С., Храпова М.В., Чечушков А.В., Олейник А.С., Кандалинцева Н.В.</copyright-holder><copyright-holder xml:lang="en">Menshchikova E.B., Serykh A.E., Romakh L.P., Petrova E.S., Khrapova M.V., Chechushkov A.V., Oleynik A.S., Kandalintseva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://sibmed.elpub.ru/jour/article/view/2450">https://sibmed.elpub.ru/jour/article/view/2450</self-uri><abstract><p>Химиотерапия по-прежнему занимает лидирующие позиции при лечении злокачественных новообразований, и крайне важным остается поиск способов и средств преодоления или смягчения ее побочных эффектов, в том числе выпадения волос (CIA, chemotherapy-induced alopecia). Несмотря на доказанную роль окислительного стресса в патогенезе CIA, число исследований по возможности применения антиоксидантов для ее предотвращения и лечения невелико. Цель настоящей работы – изучить влияние монофенола 3-(3′-трет-бутил-4′-гидpокcифенил) пpопилтиоcульфоната натpия (ТС-13), обладающего прямым и опосредованным антиоксидантным действием, на восстановление волосяного покрова у мышей при моделировании CIA.</p><sec><title>Материал и методы</title><p>Материал и методы. Исследование выполнено на 30 аутбредных мышах обоего пола, которые были разделены на четыре группы. Животные группы 1 – контроль (n = 7), мыши группы 2 за 14 дней до депиляции и на протяжении всего эксперимента получали ТС13 с питьевой водой из расчета 100 мг/кг массы тела (группа «ТС-13», n = 7), у мышей групп 3 (группа «CIA», n = 8) и 4 (группа «CIA + ТС-13», n = 8) моделировали CIA, при этом животные группы 4 на протяжении всего эксперимента получали ТС-13 с питьевой водой. У всех животных выбривали спины, обработанные участки депилировали, на 9-й день мышам групп 3 и 4 внутрибрюшинно вводили раствор циклофосфамида (120 мг/кг массы тела). В дальнейшем спины фотографировали через день и анализировали полученные изображения, на 51-й день животных выводили из эксперимента, извлекали органы (печень, сердце, левая почка, селезенка) и взвешивали.</p><p>Результаты и их обсуждение. По массе тела существенных различий между группами в динамике эксперимента не наблюдалось, обнаружена лишь тенденция к ее снижению у самцов, получавших циклофосфамид, на 17-й день (p = 0,0662). У мышей контрольной группы и получавших ТС-13 с питьевой водой интенсивный рост волос начинается на 11–13-й день эксперимента, полностью волосяной покров восстанавливается на 13–15-й день. У животных группы CIA фаза выраженного роста волос существенно сдвигается, начинаясь на 25-й день до полного зарастания на 40-й день, назначение мышам с CIA ТС-13 (группа 4) ускоряло процесс, хотя и не до значений интактного (группа 1, p = 0,015) и позитивного (группа 2, p = 0,002) контроля, быстрый рост шерсти начинался на 17-й день, полное восстановление волосяного покрова происходило на 31-й день, различие с группой 3 статистически значимо (p = 0,004).</p></sec><sec><title>Заключение</title><p>Заключение. Назначение ТС-13 ускоряет отрастание шерсти у мышей при моделировании CIA, хотя и не отменяет полностью способность циклофосфамида индуцировать потерю волос. Последнее мы склонны рассматривать как позитивный результат, свидетельствующий о том, что вещество не отменяет главное терапевтическое действие противоопухолевых средств – антипролиферативное.</p></sec></abstract><trans-abstract xml:lang="en"><p>Chemotherapy remains a mainstay in the treatment of malignant neoplasms, and the search for strategies to overcome or mitigate its side effects, including hair loss (CIA, chemotherapy-induced alopecia), remains extremely important. Despite the proven role of oxidative stress in the pathogenesis of CIA, the number of studies on the potential use of antioxidants for its prevention and treatment is limited. The aim of the study was to investigate the effect of the monophenol sodium 3-(3′-tert-butyl-4′-hydroxyphenyl) propylthiosulfonate (TS-13), which possesses direct and indirect antioxidant activity, on hair regrowth in mice modeling CIA.</p><sec><title>Material and methods</title><p>Material and methods. The study was performed on 30 outbred mice of both sexes, divided into 4 groups. Group 1 animals served as controls (n = 7). Mice in Group 2 received TS-13 in drinking water at a dose of 100 mg/kg body weight starting 14 days before depilation and throughout the experiment (Group “TS-13”, n = 7). CIA was modeled in mice of Group 3 (Group “CIA”, n = 8) and Group 4 (Group “CIA + TS-13”, n = 8). Animals in Group 4 received TS-13 in drinking water throughout the entire experiment. The backs of all animals were shaved, and the treated areas were depilated. On day 9, mice in Groups 3 and 4 received an intraperitoneal injection of cyclophosphamide solution (120 mg/kg body weight). Subsequently, the backs were photographed every other day, and the obtained images were analyzed. On day 51, the animals were euthanized, organs (liver, heart, left kidney, spleen) were extracted and weighed.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. No significant differences in body weight dynamics were observed between the groups during the experiment; only a tendency towards weight loss was detected in males receiving cyclophosphamide on day 17 (p = 0.0662). In mice of the control group and those receiving TS-13 in drinking water, intensive hair growth began on days 11–13 of the experiment, with complete hair regrowth occurring by days 13–15. In animals of the CIA group, the phase of pronounced hair growth was significantly delayed, starting on day 25 and reaching complete regrowth only by day 40. Administration of TS-13 to mice with CIA (Group 4) accelerated the process, although not to the level of the intact control (Group 1, p = 0.015) or the positive control (Group 2, p = 0.002). Rapid hair growth began on day 17, and complete hair regrowth occurred on day 31; the difference compared to Group 3 was statistically significant (p = 0.004).</p></sec><sec><title>Conclusions</title><p>Conclusions. TS-13 administration accelerates hair regrowth in mice with CIA model, although it does not completely abolish cyclophosphamide’s ability to induce hair loss. We consider the latter a positive outcome, indicating that the substance does not negate the key therapeutic effect of antitumor agents – their antiproliferative action.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>злокачественные новообразования</kwd><kwd>химиотерапия</kwd><kwd>побочное действие</kwd><kwd>антиоксиданты</kwd><kwd>Nrf2-опосредованный сигнальный путь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>malignant neoplasms</kwd><kwd>chemotherapy</kwd><kwd>adverse effects</kwd><kwd>antioxidants</kwd><kwd>Nrf2-mediated signaling pathway</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках Государственного задания ФИЦ ФТМ с использованием оборудования ЦКП «Современные оптические системы».</funding-statement><funding-statement xml:lang="en">The work was carried out within the framework of the State assignment of the FRC FTM using the equipment of the Center for Collective Use «Modern Optical Systems».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Liao Z., Chua D., Tan N.S. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol. Cancer. 2019;18(1):65. doi: 10.1186/s12943-019-0961-y</mixed-citation><mixed-citation xml:lang="en">Liao Z., Chua D., Tan N.S. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol. Cancer. 2019;18(1):65. doi: 10.1186/s12943-019-0961-y</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tiwari R., Mondal Y., Bharadwaj K., Mahajan M., Mondal S., Sarkar A. Reactive oxygen species (ROS) and their profound influence on regulating diverse aspects of cancer: A concise review. Drug Dev. Res. 2025;86(4):e70107. doi: 10.1002/ddr.70107</mixed-citation><mixed-citation xml:lang="en">Tiwari R., Mondal Y., Bharadwaj K., Mahajan M., Mondal S., Sarkar A. Reactive oxygen species (ROS) and their profound influence on regulating diverse aspects of cancer: A concise review. Drug Dev. Res. 2025;86(4):e70107. doi: 10.1002/ddr.70107</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen D., Guo Z., Yao L., Sun Y., Dian Y., Zhao D., Ke Y., Zeng F., Zhang C., Deng G., Li L. Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer. Redox Biol. 2025;84:103686. doi: 10.1016/j.redox.2025.103686</mixed-citation><mixed-citation xml:lang="en">Chen D., Guo Z., Yao L., Sun Y., Dian Y., Zhao D., Ke Y., Zeng F., Zhang C., Deng G., Li L. Targeting oxidative stress-mediated regulated cell death as a vulnerability in cancer. Redox Biol. 2025;84:103686. doi: 10.1016/j.redox.2025.103686</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson B.E., Jacob S., Yap M.L., Ferlay J., Bray F., Barton M.B. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a populationbased study. Lancet Oncol. 2019;20(6):769–780. doi: 10.1016/S1470-2045(19)30163-9</mixed-citation><mixed-citation xml:lang="en">Wilson B.E., Jacob S., Yap M.L., Ferlay J., Bray F., Barton M.B. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a populationbased study. Lancet Oncol. 2019;20(6):769–780. doi: 10.1016/S1470-2045(19)30163-9</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Oun R., Moussa Y.E., Wheate N.J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645–6653. doi: 10.1039/c8dt00838h</mixed-citation><mixed-citation xml:lang="en">Oun R., Moussa Y.E., Wheate N.J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645–6653. doi: 10.1039/c8dt00838h</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y.Q., Liu D.Q., Chen S.P., Chen N., Sun J., Wang X.M., Cao F., Tian Y.K., Ye D.W. Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain. Acta Pharmacol. Sin. 2020;41(8):1041–1048. doi: 10.1038/s41401-020-0394-6</mixed-citation><mixed-citation xml:lang="en">Zhou Y.Q., Liu D.Q., Chen S.P., Chen N., Sun J., Wang X.M., Cao F., Tian Y.K., Ye D.W. Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain. Acta Pharmacol. Sin. 2020;41(8):1041–1048. doi: 10.1038/s41401-020-0394-6</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Leskinen S., Alsalek S., Galvez R., Ononogbu-Uche F.C., Shah H.A., Vojnic M., D’Amico R.S. Chemotherapy-related cognitive impairment and changes in neural network dynamics: A systematic review. Neurology. 2025;104(2):e210130. doi: 10.1212/wnl.0000000000210130</mixed-citation><mixed-citation xml:lang="en">Leskinen S., Alsalek S., Galvez R., Ononogbu-Uche F.C., Shah H.A., Vojnic M., D’Amico R.S. Chemotherapy-related cognitive impairment and changes in neural network dynamics: A systematic review. Neurology. 2025;104(2):e210130. doi: 10.1212/wnl.0000000000210130</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Reis-Mendes A., Ferreira M., Padrao A.I., Duarte J.A., Duarte-Araujo M., Remiao F., Carvalho F., Sousa E., Bastos M.L., Costa V.M. The role of Nrf2 and inflammation on the dissimilar cardiotoxicity of doxorubicin in two-time points: a cardio-oncology in vivo study through time. Inflammation. 2024;47(1):264– 284. doi: 10.1007/s10753-023-01908-0</mixed-citation><mixed-citation xml:lang="en">Reis-Mendes A., Ferreira M., Padrao A.I., Duarte J.A., Duarte-Araujo M., Remiao F., Carvalho F., Sousa E., Bastos M.L., Costa V.M. The role of Nrf2 and inflammation on the dissimilar cardiotoxicity of doxorubicin in two-time points: a cardio-oncology in vivo study through time. Inflammation. 2024;47(1):264– 284. doi: 10.1007/s10753-023-01908-0</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wikramanayake T.C., Haberland N.I., Akhundlu A., Laboy Nieves A., Miteva M. Prevention and treatment of chemotherapy-induced alopecia: What is available and what is coming? Curr. Oncol. 2023;30(4):3609–3626. doi: 10.3390/curroncol30040275</mixed-citation><mixed-citation xml:lang="en">Wikramanayake T.C., Haberland N.I., Akhundlu A., Laboy Nieves A., Miteva M. Prevention and treatment of chemotherapy-induced alopecia: What is available and what is coming? Curr. Oncol. 2023;30(4):3609–3626. doi: 10.3390/curroncol30040275</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Aiba T., Kono Y., Etoh T., Kawano Y., Oshima Y., Inomata M. Efficacy of cooling therapy and alpha-lipoic acid derivative against chemotherapyinduced alopecia in an animal model. Cancer Sci. 2023;114(3):1007–1014. doi: 10.1111/cas.15639</mixed-citation><mixed-citation xml:lang="en">Aiba T., Kono Y., Etoh T., Kawano Y., Oshima Y., Inomata M. Efficacy of cooling therapy and alpha-lipoic acid derivative against chemotherapyinduced alopecia in an animal model. Cancer Sci. 2023;114(3):1007–1014. doi: 10.1111/cas.15639</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">He M., Jia H. Enhancing access to scalp cooling therapy: How can we move forward? A response to Novice et al’s “the financial burden of scalp cooling therapy: A nonprofit organization data analysis”. J. Am. Acad. Dermatol. 2025; Online ahead of print. doi: 10.1016/j.jaad.2025.03.093</mixed-citation><mixed-citation xml:lang="en">He M., Jia H. Enhancing access to scalp cooling therapy: How can we move forward? A response to Novice et al’s “the financial burden of scalp cooling therapy: A nonprofit organization data analysis”. J. Am. Acad. Dermatol. 2025; Online ahead of print. doi: 10.1016/j.jaad.2025.03.093</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sechi A., Cedirian S., Brunetti T., Quadrelli F., Torres F., Tosti A., Rinaldi F., Pinto D., Bolognino R., Marzano A.V., Piraccini B.M. Safety first: A comprehensive review of nutritional supplements for hair loss in breast cancer patients. Nutrients. 2025;17(9):1451. doi: 10.3390/nu17091451</mixed-citation><mixed-citation xml:lang="en">Sechi A., Cedirian S., Brunetti T., Quadrelli F., Torres F., Tosti A., Rinaldi F., Pinto D., Bolognino R., Marzano A.V., Piraccini B.M. Safety first: A comprehensive review of nutritional supplements for hair loss in breast cancer patients. Nutrients. 2025;17(9):1451. doi: 10.3390/nu17091451</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Perez S.M., Vattigunta M., Kelly C., Eber A. Low-level laser and LED therapy in alopecia: A systematic review and meta-analysis. Dermatol. Surg. 2025;51(2):179–183. doi: 10.1097/ DSS.0000000000004442</mixed-citation><mixed-citation xml:lang="en">Perez S.M., Vattigunta M., Kelly C., Eber A. Low-level laser and LED therapy in alopecia: A systematic review and meta-analysis. Dermatol. Surg. 2025;51(2):179–183. doi: 10.1097/ DSS.0000000000004442</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Amaya C., Smith E.R., Xu X.X. Low intensity ultrasound as an antidote to taxane/paclitaxel-induced cytotoxicity. J. Cancer. 2022;13(7):2362–2373. doi: 10.7150/jca.71263</mixed-citation><mixed-citation xml:lang="en">Amaya C., Smith E.R., Xu X.X. Low intensity ultrasound as an antidote to taxane/paclitaxel-induced cytotoxicity. J. Cancer. 2022;13(7):2362–2373. doi: 10.7150/jca.71263</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Majewski M., Gardas K., Waskiel-Burnat A., Ordak M., Rudnicka L. The role of minoxidil in treatment of alopecia areata: A systematic review and metaanalysis. J. Clin. Med. 2024;13(24):7712. doi: 10.3390/jcm13247712</mixed-citation><mixed-citation xml:lang="en">Majewski M., Gardas K., Waskiel-Burnat A., Ordak M., Rudnicka L. The role of minoxidil in treatment of alopecia areata: A systematic review and metaanalysis. J. Clin. Med. 2024;13(24):7712. doi: 10.3390/jcm13247712</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Jimenez J.J. Mild oxidative stress protects against chemotherapy-induced hair loss. Front. Oncol. 2022;12:1078916. doi: 10.3389/fonc.2022.1078916</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Jimenez J.J. Mild oxidative stress protects against chemotherapy-induced hair loss. Front. Oncol. 2022;12:1078916. doi: 10.3389/fonc.2022.1078916</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Меньщикова Е.Б., Храпова М.В., Кожин П.М., Чечушков А.В., Петрова Е.С., Серых А.Е., Ромах Л.П., Кандалинцева Н.В. Оригинальный синтетический монофенольный антиоксидант комбинированного действия угнетает рост опухоли in vivo. Сиб. науч. мед. ж. 2024;44(6):128–137. doi: 10.18699/SSMJ20240612.</mixed-citation><mixed-citation xml:lang="en">Menshchikova E.B., Khrapova M.V., Kozhin P.M., Chechushkov A.V., Petrova E.S., Serykh A.E., Romakh L.P., Kandalintseva N.V. Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2024;44(6):128–137. [In Russian]. doi: 10.18699/SSMJ20240612.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Menshchikova E.B., Knyazev R.A., Trifonova N.V., Deeva N.A., Kolpakov A.R., Romakh L.P., Kandalintseva N.V. Synthetic antioxidant TS13 reduces the cardiotoxicity of doxorubicin. Cell Tissue Biol. 2024;18(5):570–578. doi: 10.1134/s1990519x24700445</mixed-citation><mixed-citation xml:lang="en">Menshchikova E.B., Knyazev R.A., Trifonova N.V., Deeva N.A., Kolpakov A.R., Romakh L.P., Kandalintseva N.V. Synthetic antioxidant TS13 reduces the cardiotoxicity of doxorubicin. Cell Tissue Biol. 2024;18(5):570–578. doi: 10.1134/s1990519x24700445</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Stenn K.S., Paus R. Controls of hair follicle cycling. Physiol. Rev. 2001;81(1):449–494. doi: 10.1152/physrev.2001.81.1.449</mixed-citation><mixed-citation xml:lang="en">Stenn K.S., Paus R. Controls of hair follicle cycling. Physiol. Rev. 2001;81(1):449–494. doi: 10.1152/physrev.2001.81.1.449</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Paus R., Handjiski B., Eichmuller S., Czarnetzki B.M. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am. J. Pathol. 1994;144(4):719–734.</mixed-citation><mixed-citation xml:lang="en">Paus R., Handjiski B., Eichmuller S., Czarnetzki B.M. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am. J. Pathol. 1994;144(4):719–734.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Серых А.Е. Интерактивная система обработки изображений с автоматической генерацией отчетов. Cвидетельство о государственной регистрации программы для ЭВМ № 2025613112; опубл. 28.01.2025.</mixed-citation><mixed-citation xml:lang="en">Серых А.Е. Интерактивная система обработки изображений с автоматической генерацией отчетов. Cвидетельство о государственной регистрации программы для ЭВМ № 2025613112; опубл. 28.01.2025.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Elso C.M., Roberts L.J., Smyth G.K., Thomson R.J., Baldwin T.M., Foote S.J., Handman E. Leishmaniasis host response loci (lmr1-3) modify disease severity through a Th1/Th2-independent pathway. Genes Immun. 2004;5(2):93–100. doi: 10.1038/sj.gene.6364042</mixed-citation><mixed-citation xml:lang="en">Elso C.M., Roberts L.J., Smyth G.K., Thomson R.J., Baldwin T.M., Foote S.J., Handman E. Leishmaniasis host response loci (lmr1-3) modify disease severity through a Th1/Th2-independent pathway. Genes Immun. 2004;5(2):93–100. doi: 10.1038/sj.gene.6364042</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hendrix S., Handjiski B., Peters E.M., Paus R. A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J. Invest. Dermatol. 2005;125(1):42– 51. doi: 10.1111/j.0022-202X.2005.23787.x</mixed-citation><mixed-citation xml:lang="en">Hendrix S., Handjiski B., Peters E.M., Paus R. A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J. Invest. Dermatol. 2005;125(1):42– 51. doi: 10.1111/j.0022-202X.2005.23787.x</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Welle M.M. Basic principles of hair follicle structure, morphogenesis, and regeneration. Vet. Pathol. 2023;60(6):732–747. doi: 10.1177/03009858231176561</mixed-citation><mixed-citation xml:lang="en">Welle M.M. Basic principles of hair follicle structure, morphogenesis, and regeneration. Vet. Pathol. 2023;60(6):732–747. doi: 10.1177/03009858231176561</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S.S., Zhang Y., Lu Q.L., Lin Z., Zhao Y. Preventive effects of cedrol against alopecia in cyclophosphamide-treated mice. Environ. Toxicol. Pharmacol. 2016;46:270–276. doi: 10.1016/j.etap.2016.07.020</mixed-citation><mixed-citation xml:lang="en">Chen S.S., Zhang Y., Lu Q.L., Lin Z., Zhao Y. Preventive effects of cedrol against alopecia in cyclophosphamide-treated mice. Environ. Toxicol. Pharmacol. 2016;46:270–276. doi: 10.1016/j.etap.2016.07.020</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jadkauskaite L., Coulombe P.A., Schafer M., Dinkova-Kostova A.T., Paus R., Haslam I.S. Oxidative stress management in the hair follicle: Could targeting NRF2 counter age-related hair disorders and beyond? Bioessays. 2017;39(8):1700029. doi: 10.1002/bies.201700029</mixed-citation><mixed-citation xml:lang="en">Jadkauskaite L., Coulombe P.A., Schafer M., Dinkova-Kostova A.T., Paus R., Haslam I.S. Oxidative stress management in the hair follicle: Could targeting NRF2 counter age-related hair disorders and beyond? Bioessays. 2017;39(8):1700029. doi: 10.1002/bies.201700029</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Храпова М.В., Брюшинина О.С., Зюзькова Ю.Г., Кандалинцева Н.В., Меньщикова Е.Б. Новыйсинтетический монофенольный антиоксидант ТС-13 проникает через гематоэнцефалический барьер. Сиб. науч. мед. ж. 2023;43(5):127–134. doi: 10.18699/SSMJ20230513.</mixed-citation><mixed-citation xml:lang="en">Khrapova M.V., Bryushinina O.S., Zyuzkova Yu.G., Kandalintseva N.V., Menshchikova E.B. New synthetic monophenolic antioxidant TS-13 penetrates the bloodbrain barrier. Sibirskij nauchnyj medicinskij zhurnal = Siberian Scientific Medical Journal. 2023;43(5):127– 134. [In Russian]. doi: 10.18699/SSMJ20230513 28. Perez A.M., Haberland N.I., Miteva M., Wikramanayake T.C. Chemotherapy-induced alopecia by docetaxel: Prevalence, treatment and prevention. Curr Oncol. 2024;31(9):5709–5721. doi: 10.3390/curroncol31090423.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
